Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AbbVie : Form 8.3 - Allergan Plc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 10:28am EDT
TIDM0Y7T TIDM0QCV 
 
 
   FORM 8.3 
 
   IRISH TAKEOVER PANEL 
 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, 
TAKEOVER RULES, 2013 
 
   DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 
1% OR MORE 
 
   1. KEY INFORMATION 
 
 
 
 
Name of person dealing (Note 1)                State Street Global Advisors & 
                                               Affiliates 
---------------------------------------------  ------------------------------- 
Company dealt in                               Allergan plc 
---------------------------------------------  ------------------------------- 
Class of relevant security to which            US$0.0001 ordinary shares 
 the dealings being disclosed relate (Note 2) 
---------------------------------------------  ------------------------------- 
Date of dealing                                03(rd) September 2019 
---------------------------------------------  ------------------------------- 
 
 
 
   2. INTERESTS AND SHORT POSITIONS 
 
   (a) Interests and short positions (following dealing) in the class of 
relevant security dealt in (Note 3) 
 
 
 
 
                                               Long             Short 
-------------------------------------  --------------------  ----------- 
                                         Number      (%)     Number  (%) 
-------------------------------------  ----------  --------  ------  --- 
(1) Relevant securities                14,925,239  4.55282% 
-------------------------------------  ----------  --------  ------  --- 
(2) Derivatives (other than options)          N/A 
-------------------------------------  ----------  --------  ------  --- 
(3) Options and agreements to 
 purchase/sell                                N/A 
-------------------------------------  ----------  --------  ------  --- 
Total                                  14,925,239  4.55282% 
-------------------------------------  ----------  --------  ------  --- 
 
 
   (b) Interests and short positions in relevant securities of the company, 
other than the class dealt in (Note 3) 
 
 
 
 
Class of relevant security:                     Long         Short 
-------------------------------------------  -----------  ----------- 
                                             Number  (%)  Number  (%) 
-------------------------------------------  ------  ---  ------  --- 
(1) Relevant securities                       N/A 
-------------------------------------------  ------  ---  ------  --- 
(2) Derivatives (other than options)          N/A 
-------------------------------------------  ------  ---  ------  --- 
(3) Options and agreements to purchase/sell   N/A 
-------------------------------------------  ------  ---  ------  --- 
Total                                         N/A 
-------------------------------------------  ------  ---  ------  --- 
 
 
   3. DEALINGS (Note 4) 
 
   (a) Purchases and sales 
 
 
 
 
Purchase/sale   Number of relevant securities  Price per unit (Note 5) 
--------------  -----------------------------  ----------------------- 
   Purchase                               100                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                               400                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                             4,900                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                             3,304                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                                43                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                               112                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                                56                   159.80 
--------------  -----------------------------  ----------------------- 
   Purchase                               100                   159.49 
--------------  -----------------------------  ----------------------- 
     Sale                                 300                   159.30 
--------------  -----------------------------  ----------------------- 
     Sale                                 400                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                               4,900                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                               1,970                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                               6,660                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                              12,025                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                              10,738                   159.80 
--------------  -----------------------------  ----------------------- 
     Sale                               3,615                   159.80 
--------------  -----------------------------  ----------------------- 
 
 
   (b) Derivatives transactions (other than options transactions) 
 
 
 
 
Product name,  Nature of transaction  Number of relevant securities  Price per unit 
 e.g. CFD       (Note 6)               (Note 7)                       (Note 5) 
-------------  ---------------------  -----------------------------  -------------- 
N/A 
-------------  ---------------------  -----------------------------  -------------- 
 
 
 
   (c) Options transactions in respect of existing relevant securities 
 
   (i) Writing, selling, purchasing or varying 
 
 
 
 
Product name,      Writing, selling,  Number of             Exercise  Type, e.g.      Expiry  Option money 
 e.g. call option   purchasing         securities to which   price     American,       date    paid/received 
                    varying etc.       the option relates              European etc.           per unit (Note 5) 
                                       (Note 7) 
-----------------  -----------------  --------------------  --------  --------------  ------  ------------------ 
N/A 
-----------------  -----------------  --------------------  --------  --------------  ------  ------------------ 
 
 
   (ii) Exercising 
 
 
 
 
Product name,      Number of securities  Exercise price per 
 e.g. call option                           unit (Note 5) 
-----------------  --------------------  ------------------ 
N/A 
-----------------  --------------------  ------------------ 
 
 
   (d) Other dealings (including transactions in respect of new securities) 
(Note 4) 
 
 
 
 
Nature of transaction  Details       Price per unit 
 (Note 8)                        (if applicable) (Note 5) 
---------------------  -------  ------------------------- 
N/A 
---------------------  -------  ------------------------- 
 
 
   4. OTHER INFORMATION 
 
   Agreements, arrangements or understandings relating to options or 
derivatives 
 
 
 
 
Full details of any agreement, arrangement or understanding 
 between the person disclosing and any other person 
 relating to the voting rights of any relevant securities 
 under any option referred to on this form or relating 
 to the voting rights or future acquisition or disposal 
 of any relevant securities to which any derivative 
 referred to on this form is referenced. If none, this 
 should be stated. 
----------------------------------------------------------- 
N/A 
----------------------------------------------------------- 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                       NO 
-------------------------------------------------------  --------------------- 
Date of disclosure                                       04(th) September 2019 
-------------------------------------------------------  --------------------- 
Contact name                                                  Chetan Shah 
-------------------------------------------------------  --------------------- 
Telephone number                                                  020 33956564 
-------------------------------------------------------  --------------------- 
If a connected EFM, name of offeree/offeror with which   N/A 
 connected 
-------------------------------------------------------  --------------------- 
If a connected EFM, state nature of connection (Note     N/A 
 10) 
-------------------------------------------------------  --------------------- 
 
 
 
 
 
 

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -0.45% 70.51 Delayed Quote.-23.52%
ALLERGAN PLC -0.13% 166.14 Delayed Quote.24.30%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
09/13GILEAD SCIENCES : Louisiana's Deal for Hepatitis C Drugs May Serve as Model -- J..
DJ
09/13GILEAD SCIENCES : Louisiana's Deal for Hepatitis C Drugs May Serve as Model -- J..
DJ
09/12ABBVIE : Form 8.3 -
DJ
09/12ABBVIE : Form 8.3 -
AQ
09/11UPDATE : Form 8.3 - AbbVie Inc (Correction of Doc)
AQ
09/09ABBVIE : Declares Quarterly Dividend
AQ
09/06ABBVIE : Declares Quarterly Dividend
PR
09/04ABBVIE : Form 8.3 - Allergan Plc
DJ
09/04ABBVIE : Form 8.3 - AbbVie Inc
AQ
08/30ABBVIE : Report of unscheduled material events or corporate event
PU
More news